FDA label bcc27cd7-e3ac-4ec3-ba94-7bcaaf9bcf10

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
d049bfcf-0634-4649-a782-12976ee4c49e
SPL ID
bcc27cd7-e3ac-4ec3-ba94-7bcaaf9bcf10
Version
1
Effective date
2011-03-01
Source export date
2026-10-12
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/7928c8e8c6256620071a8b7e5b93eb8dfa543649c08d17a01ea02251012ba58c/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 01:25:32

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 3 of 3 · 11 matching rows.

warnings

Cognitive/ Neuropsychiatric Adverse Events: Use of zonisamide capsules was frequently associated with central nervous system-related adverse events. The most significant of these can be classified into three general categories: 1) psychiatric symptoms, including depression and psychosis, 2) psychomotor slowing, difficulty with concentration, and speech or language problems, in particular, word-finding difficulties, and 3) somnolence or fatigue. In placebo-controlled trials, 2.2% of patients discontinued zonisamide capsules or were hospitalized for depression compared to 0.4% of placebo patients. Among all epilepsy patients treated with zonisamide capsules, 1.4% were discontinued and 1.0% were hospitalized because of reported depression or suicide attempts. In placebo-controlled trials, 2.2% of patients discontinued zonisamide capsules or were hospitalized due to psychosis or psychosis-related symptoms compared to none of the placebo patients. Among all epilepsy patients treated with zonisamide capsules, 0.9% were discontinued and 1.4% were hospitalized because of reported psychosis or related symptoms. Psychomotor slowing and difficulty with concentration occurred in the first month of treatment and were associated with doses above 300 mg/day. Speech and language problems tended to occur after 6-10 weeks of treatment and at doses above 300 mg/day. Although in most cases these events were of mild to moderate severity, they at times led to withdrawal from treatment. Somnolence and fatigue were frequently reported CNS adverse events during clinical trials with zonisamide capsules. Although in most cases these events were of mild to moderate severity, they led to withdrawal from treatment in 0.2% of the patients enrolled in controlled trials. Somnolence and fatigue tended to occur within the first month of treatment. Somnolence and fatigue occurred most frequently at doses of 300-500 mg/day. Patients should be cautioned about this possibility and special care should be taken by patients if they drive, operate machinery, or perform any hazardous task.

warnings table

<table ID="i5d84b5d8-7d93-4148-8954-dd18ff66ed04" width="100%"> <caption>Table 3: Risk by indication for antiepileptic drugs in the pooled analysis</caption> <thead> <tr> <th>Indication </th> <th>Placebo Patients with Events Per 1000 Patients</th> <th>Drug Patients with Events Per 1000 Patients</th> <th>Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients </th> <th>Risk Difference: Drug Patients with Events Per 1000 Patients</th> </tr> </thead> <tbody> <tr> <td>Epilepsy</td> <td> 1.0 </td> <td> 3.4 </td> <td> 3.5</td> <td> 2.4</td> </tr> <tr> <td>Psychiatric </td> <td> 5.7 </td> <td> 8.5 </td> <td> 1.5</td> <td> 2.9</td> </tr> <tr> <td> Other </td> <td> 1.0 </td> <td> 1.8</td> <td> 1.9 </td> <td> 0.9</td> </tr> <tr> <td> Total </td> <td> 2.4 </td> <td> 4.3 </td> <td> 1.8</td> <td> 1.9</td> </tr> </tbody> </table>

warnings table

<table ID="i5d84b5d8-7d93-4148-8954-dd18ff66ed04" width="100%"> <caption>Table 3: Risk by indication for antiepileptic drugs in the pooled analysis</caption> <thead> <tr> <th>Indication </th> <th>Placebo Patients with Events Per 1000 Patients</th> <th>Drug Patients with Events Per 1000 Patients</th> <th>Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients </th> <th>Risk Difference: Drug Patients with Events Per 1000 Patients</th> </tr> </thead> <tbody> <tr> <td>Epilepsy</td> <td> 1.0 </td> <td> 3.4 </td> <td> 3.5</td> <td> 2.4</td> </tr> <tr> <td>Psychiatric </td> <td> 5.7 </td> <td> 8.5 </td> <td> 1.5</td> <td> 2.9</td> </tr> <tr> <td> Other </td> <td> 1.0 </td> <td> 1.8</td> <td> 1.9 </td> <td> 0.9</td> </tr> <tr> <td> Total </td> <td> 2.4 </td> <td> 4.3 </td> <td> 1.8</td> <td> 1.9</td> </tr> </tbody> </table>

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 5 matching rows.

adverse reactions

ADVERSE REACTIONS The most commonly observed adverse events related to treatment with zonisamide capsules (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency were somnolence, anorexia, dizziness, ataxia, agitation/irritability, and difficulty with memory and/or concentration. In controlled clinical trials, 12% of patients receiving zonisamide capsules as adjunctive therapy discontinued due to an adverse event compared to 6% receiving placebo. Approximately 21% of the 1,336 patients with epilepsy who received zonisamide capsules in clinical studies discontinued treatment because of an adverse event. The adverse events most commonly associated with discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). Many of these adverse events were dose-related (see WARNINGS and PRECAUTIONS ). Adverse Event Incidence in Controlled Clinical Trials: Table 4 lists treatment-emergent adverse events that occurred in at least 2% of patients treated with zonisamide capsules in controlled clinical trials that were numerically more common in the zonisamide capsules group. In these studies, either zonisamide capsules or placebo was added to the patient's current AED therapy. Adverse events were usually mild or moderate in intensity. The prescriber should be aware that these figures, obtained when zonisamide capsules was added to concurrent AED therapy, cannot be used to predict the frequency of adverse events in the course of usual medical practice when patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis by which to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied. TABLE 4: Incidence (%) of Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Trials (Events that occurred in at least 2% of zonisamide capsules-treated patients and occurred more frequently in zonisamide capsules-treated than placebo-treated patients) BODY SYSTEM/PREFERRED TERM Zonisamide Capsules (n=269) % Placebo (n=230) % BODY AS A WHOLE Headache 10 8 Abdominal Pain 6 3 Flu Syndrome 4 3 DIGESTIVE Anorexia 13 6 Nausea 9 6 Diarrhea 5 2 Dyspepsia 3 1 Constipation 2 1 Dry Mouth 2 1 HEMATOLOGIS AND LYMPHATIC Ecchymosis 2 1 METABOLIC AND NUTRITIONAL Weight Loss 3 2 NERVOUS SYSTEM Dizziness 13 7 Ataxia 6 1 Nystagmus 4 2 Paresthesia 4 1 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-ALERTED COGNITIVE FUNCTION Confusion 6 3 Difficulty Concentrating 6 2 Difficulty with Memory 6 2 Mental Slowing 4 2 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-BEHAVIORAL ABNORMALITIES (NON-PSYCHOSIS-RELATED) Agitation/Irritability 9 4 Depression 6 3 Insomnia 6 3 Anxiety 3 2 Nervousness 2 1 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-BEHAVIORAL ABNORMALITIES (PSYCHOSIS-RELATED) Schizophrenic/Schizophreniform Behavior 2 0 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-CNS DEPRESSION Somnolence 17 7 Fatigue 8 6 Tiredness 7 5 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-SPEECH AND LANGUAGE ABNORMALITIES Speech Abnormalities 5 2 Difficulties in Verbal Expression 2 <1 RESPIRATORY Rhinitis 2 1 SKIN AND APPENDAGES Rash 3 2 SPECIAL SENSES Diplopia 6 3 Taste Perversion 2 0 Other Adverse Events Observed During Clinical Trials: Zonisamide capsules has been administered to 1,598 individuals during all clinical trials, only some of which were placebo-controlled. During these trials, all events were recorded by investigators using their own terms. To provide a useful estimate of the proportion of individuals having adverse events, similar events have been grouped into a smaller number of standardized categories using a modified COSTART dictionary. The frequencies represent the proportion of the 1,598 individuals exposed to zonisamide capsules who experienced an event on at least one occasion. All events are included except those already listed in the previous table or discussed in WARNINGS or PRECAUTIONS , trivial events, those too general to be informative, and those not reasonably associated with zonisamide capsules. Events are further classified within each category and listed in order of decreasing frequency as follows: frequent occurring in at least 1:100 patient; infrequent occurring in 1:100 to 1:1000 patients; rare occurring in fewer than 1:1000 patients. Body as a Whole: Frequent: Accidental injury, asthenia. Infrequent: Chest pain, flank pain, malaise, allergic reaction, face edema, neck rigidity. Rare: Lupus erythematosus. Cardiovascular: Infrequent: Palpitation, tachycardia, vascular insufficiency, hypotension, hypertension, thrombophlebitis, syncope, bradycardia. Rare: Atrial fibrillation, heart failure, pulmonary embolus, ventricular extrasystoles. Digestive: Frequent: Vomiting. Infrequent: Flatulence, gingivitis, gum hyperplasia, gastritis, gastroenteritis, stomatitis, cholelithiasis, glossitis, melena, rectal hemorrhage, ulcerative stomatitis, gastro-duodenal ulcer, dysphagia, gum hemorrhage. Rare: Cholangitis, hematemesis, cholecystitis, cholestatic jaundice, colitis, duodenitis, esophagitis, fecal incontinence, mouth ulceration. Hematologic and Lymphatic: Infrequent: Leukopenia, anemia, immunodeficiency, lymphadenopathy. Rare: Thrombocytopenia, microcytic anemia, petechia. Metabolic and Nutritional: Infrequent: Peripheral edema, weight gain, edema, thirst, dehydration. Rare: Hypoglycemia, hyponatremia, lactic dehydrogenase increased, SGOT increased, SGPT increased. Musculoskeletal: Infrequent: Leg cramps, myalgia, myasthenia, arthralgia, arthritis. Nervous System: Frequent: Tremor, convulsion, abnormal gait, hyperesthesia, incoordination. Infrequent: Hypertonia, twitching, abnormal dreams, vertigo, libido decreased, neuropathy, hyperkinesia, movement disorder, dysarthria, cerebrovascular accident, hypotonia, peripheral neuritis, reflexes increased. Rare: Dyskinesia, dystonia, encephalopathy, facial paralysis, hypokinesia, hyperesthesia, myoclonus, oculogyric crisis. Behavioral Abnormalities - Non-Psychosis-Related: Infrequent: Euphoria. Respiratory: Frequent: Pharyngitis, cough increased. Infrequent: Dyspnea. Rare: Apnea, hemoptysis. Skin and Appendages: Frequent: Pruritus. Infrequent: Maculopapular rash, acne, alopecia, dry skin, sweating, eczema, urticaria, hirsutism, pustular rash, vesiculobullous rash. Special Senses: Frequent: Amblyopia, tinnitus. Infrequent: Conjunctivitis, parosmia, deafness, visual field defect, glaucoma. Rare: Photophobia, iritis. Urogenital: Infrequent: Urinary frequency, dysuria, urinary incontinence, hematuria, impotence, urinary retention, urinary urgency, amenorrhea, polyuria, nocturia. Rare: Albuminuria, enuresis, bladder pain, bladder calculus, gynecomastia, mastitis, menorrhagia.

adverse reactions

Adverse Event Incidence in Controlled Clinical Trials: Table 4 lists treatment-emergent adverse events that occurred in at least 2% of patients treated with zonisamide capsules in controlled clinical trials that were numerically more common in the zonisamide capsules group. In these studies, either zonisamide capsules or placebo was added to the patient's current AED therapy. Adverse events were usually mild or moderate in intensity. The prescriber should be aware that these figures, obtained when zonisamide capsules was added to concurrent AED therapy, cannot be used to predict the frequency of adverse events in the course of usual medical practice when patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis by which to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied. TABLE 4: Incidence (%) of Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Trials (Events that occurred in at least 2% of zonisamide capsules-treated patients and occurred more frequently in zonisamide capsules-treated than placebo-treated patients) BODY SYSTEM/PREFERRED TERM Zonisamide Capsules (n=269) % Placebo (n=230) % BODY AS A WHOLE Headache 10 8 Abdominal Pain 6 3 Flu Syndrome 4 3 DIGESTIVE Anorexia 13 6 Nausea 9 6 Diarrhea 5 2 Dyspepsia 3 1 Constipation 2 1 Dry Mouth 2 1 HEMATOLOGIS AND LYMPHATIC Ecchymosis 2 1 METABOLIC AND NUTRITIONAL Weight Loss 3 2 NERVOUS SYSTEM Dizziness 13 7 Ataxia 6 1 Nystagmus 4 2 Paresthesia 4 1 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-ALERTED COGNITIVE FUNCTION Confusion 6 3 Difficulty Concentrating 6 2 Difficulty with Memory 6 2 Mental Slowing 4 2 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-BEHAVIORAL ABNORMALITIES (NON-PSYCHOSIS-RELATED) Agitation/Irritability 9 4 Depression 6 3 Insomnia 6 3 Anxiety 3 2 Nervousness 2 1 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-BEHAVIORAL ABNORMALITIES (PSYCHOSIS-RELATED) Schizophrenic/Schizophreniform Behavior 2 0 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-CNS DEPRESSION Somnolence 17 7 Fatigue 8 6 Tiredness 7 5 NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-SPEECH AND LANGUAGE ABNORMALITIES Speech Abnormalities 5 2 Difficulties in Verbal Expression 2 <1 RESPIRATORY Rhinitis 2 1 SKIN AND APPENDAGES Rash 3 2 SPECIAL SENSES Diplopia 6 3 Taste Perversion 2 0

adverse reactions

Other Adverse Events Observed During Clinical Trials: Zonisamide capsules has been administered to 1,598 individuals during all clinical trials, only some of which were placebo-controlled. During these trials, all events were recorded by investigators using their own terms. To provide a useful estimate of the proportion of individuals having adverse events, similar events have been grouped into a smaller number of standardized categories using a modified COSTART dictionary. The frequencies represent the proportion of the 1,598 individuals exposed to zonisamide capsules who experienced an event on at least one occasion. All events are included except those already listed in the previous table or discussed in WARNINGS or PRECAUTIONS , trivial events, those too general to be informative, and those not reasonably associated with zonisamide capsules. Events are further classified within each category and listed in order of decreasing frequency as follows: frequent occurring in at least 1:100 patient; infrequent occurring in 1:100 to 1:1000 patients; rare occurring in fewer than 1:1000 patients. Body as a Whole: Frequent: Accidental injury, asthenia. Infrequent: Chest pain, flank pain, malaise, allergic reaction, face edema, neck rigidity. Rare: Lupus erythematosus. Cardiovascular: Infrequent: Palpitation, tachycardia, vascular insufficiency, hypotension, hypertension, thrombophlebitis, syncope, bradycardia. Rare: Atrial fibrillation, heart failure, pulmonary embolus, ventricular extrasystoles. Digestive: Frequent: Vomiting. Infrequent: Flatulence, gingivitis, gum hyperplasia, gastritis, gastroenteritis, stomatitis, cholelithiasis, glossitis, melena, rectal hemorrhage, ulcerative stomatitis, gastro-duodenal ulcer, dysphagia, gum hemorrhage. Rare: Cholangitis, hematemesis, cholecystitis, cholestatic jaundice, colitis, duodenitis, esophagitis, fecal incontinence, mouth ulceration. Hematologic and Lymphatic: Infrequent: Leukopenia, anemia, immunodeficiency, lymphadenopathy. Rare: Thrombocytopenia, microcytic anemia, petechia. Metabolic and Nutritional: Infrequent: Peripheral edema, weight gain, edema, thirst, dehydration. Rare: Hypoglycemia, hyponatremia, lactic dehydrogenase increased, SGOT increased, SGPT increased. Musculoskeletal: Infrequent: Leg cramps, myalgia, myasthenia, arthralgia, arthritis. Nervous System: Frequent: Tremor, convulsion, abnormal gait, hyperesthesia, incoordination. Infrequent: Hypertonia, twitching, abnormal dreams, vertigo, libido decreased, neuropathy, hyperkinesia, movement disorder, dysarthria, cerebrovascular accident, hypotonia, peripheral neuritis, reflexes increased. Rare: Dyskinesia, dystonia, encephalopathy, facial paralysis, hypokinesia, hyperesthesia, myoclonus, oculogyric crisis. Behavioral Abnormalities - Non-Psychosis-Related: Infrequent: Euphoria. Respiratory: Frequent: Pharyngitis, cough increased. Infrequent: Dyspnea. Rare: Apnea, hemoptysis. Skin and Appendages: Frequent: Pruritus. Infrequent: Maculopapular rash, acne, alopecia, dry skin, sweating, eczema, urticaria, hirsutism, pustular rash, vesiculobullous rash. Special Senses: Frequent: Amblyopia, tinnitus. Infrequent: Conjunctivitis, parosmia, deafness, visual field defect, glaucoma. Rare: Photophobia, iritis. Urogenital: Infrequent: Urinary frequency, dysuria, urinary incontinence, hematuria, impotence, urinary retention, urinary urgency, amenorrhea, polyuria, nocturia. Rare: Albuminuria, enuresis, bladder pain, bladder calculus, gynecomastia, mastitis, menorrhagia.

adverse reactions table

<table width="75%" ID="i88df24fc-30e0-4523-815a-4008f0b4d361"> <caption>TABLE 4: Incidence (%) of Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Trials (Events that occurred in at least 2% of zonisamide capsules-treated patients and occurred more frequently in zonisamide capsules-treated than placebo-treated patients) </caption> <col align="left" valign="top" width="50%"/> <col align="center" valign="top" width="25%"/> <col align="center" valign="top" width="25%"/> <thead> <tr> <th>BODY SYSTEM/PREFERRED TERM</th> <th>Zonisamide Capsules (n=269) %</th> <th>Placebo (n=230) %</th> </tr> </thead> <tbody> <tr> <td> <content styleCode="bold">BODY AS A WHOLE</content> </td> <td/> <td/> </tr> <tr> <td> Headache</td> <td>10</td> <td>8</td> </tr> <tr> <td> Abdominal Pain</td> <td>6</td> <td>3</td> </tr> <tr> <td> Flu Syndrome</td> <td>4</td> <td>3</td> </tr> <tr> <td> <content styleCode="bold">DIGESTIVE</content> </td> <td/> <td/> </tr> <tr> <td> Anorexia</td> <td>13</td> <td>6</td> </tr> <tr> <td> Nausea</td> <td>9</td> <td>6</td> </tr> <tr> <td> Diarrhea</td> <td>5</td> <td>2</td> </tr> <tr> <td> Dyspepsia</td> <td>3</td> <td>1</td> </tr> <tr> <td> Constipation</td> <td>2</td> <td>1</td> </tr> <tr> <td> Dry Mouth</td> <td>2</td> <td>1</td> </tr> <tr> <td> <content styleCode="bold">HEMATOLOGIS AND LYMPHATIC</content> </td> <td/> <td/> </tr> <tr> <td> Ecchymosis</td> <td>2</td> <td>1</td> </tr> <tr> <td> <content styleCode="bold">METABOLIC AND NUTRITIONAL</content> </td> <td/> <td/> </tr> <tr> <td> Weight Loss</td> <td>3</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold">NERVOUS SYSTEM</content> </td> <td/> <td/> </tr> <tr> <td> Dizziness</td> <td>13</td> <td>7</td> </tr> <tr> <td> Ataxia</td> <td>6</td> <td>1</td> </tr> <tr> <td> Nystagmus</td> <td>4</td> <td>2</td> </tr> <tr> <td> Paresthesia</td> <td>4</td> <td>1</td> </tr> <tr> <td> <content styleCode="bold">NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-ALERTED COGNITIVE FUNCTION</content> </td> <td/> <td/> </tr> <tr> <td> Confusion</td> <td>6</td> <td>3</td> </tr> <tr> <td> Difficulty Concentrating</td> <td>6</td> <td>2</td> </tr> <tr> <td> Difficulty with Memory</td> <td>6</td> <td>2</td> </tr> <tr> <td> Mental Slowing</td> <td>4</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold">NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-BEHAVIORAL ABNORMALITIES (NON-PSYCHOSIS-RELATED)</content> </td> <td/> <td/> </tr> <tr> <td> Agitation/Irritability</td> <td>9</td> <td>4</td> </tr> <tr> <td> Depression</td> <td>6</td> <td>3</td> </tr> <tr> <td> Insomnia</td> <td>6</td> <td>3</td> </tr> <tr> <td> Anxiety</td> <td>3</td> <td>2</td> </tr> <tr> <td> Nervousness</td> <td>2</td> <td>1</td> </tr> <tr> <td> <content styleCode="bold">NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-BEHAVIORAL ABNORMALITIES (PSYCHOSIS-RELATED)</content> </td> <td/> <td/> </tr> <tr> <td> Schizophrenic/Schizophreniform Behavior</td> <td>2</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-CNS DEPRESSION</content> </td> <td/> <td/> </tr> <tr> <td> Somnolence</td> <td>17</td> <td>7</td> </tr> <tr> <td> Fatigue</td> <td>8</td> <td>6</td> </tr> <tr> <td> Tiredness</td> <td>7</td> <td>5</td> </tr> <tr> <td> <content styleCode="bold">NEUROPSYCHIATRIC AND COGNITIVE DYSFUNCTION-SPEECH AND LANGUAGE ABNORMALITIES</content> </td> <td/> <td/> </tr> <tr> <td> Speech Abnormalities</td> <td>5</td> <td>2</td> </tr> <tr> <td> Difficulties in Verbal Expression</td> <td>2</td> <td>&lt;1</td> </tr> <tr> <td> <content styleCode="bold">RESPIRATORY</content> </td> <td/> <td/> </tr> <tr> <td> Rhinitis</td> <td>2</td> <td>1</td> </tr> <tr> <td> <content styleCode="bold">SKIN AND APPENDAGES</content> </td> <td/> <td/> </tr> <tr> <td> Rash</td> <td>3</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold">SPECIAL SENSES</content> </td> <td/> <td/> </tr> <tr> <td> Diplopia</td> <td>6</td> <td>3</td> </tr> <tr> <td> Taste Perversion</td> <td>2</td> <td>0</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.